|
31.3.2022 |
GA |
Iris Oifigiúil an Aontais Eorpaigh |
C 144/1 |
Achoimre ar chinntí an Aontais Eorpaigh maidir le húdaruithe margaíochta i ndáil le táirgí íocshláinte ó 1 Feabhra 2022 go dtí 28 Feabhra 2022
(Arna fhoilsiú de bhun Airteagal 13 nó Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle (1))
(2022/C 144/01)
— Údarú margaíochta a eisiúint (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
ANI (an tAinm Neamhdhílseánaigh Idirnáisiúnta) |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Foirm chógaisíochta |
An Cód CAT (an Cód Ceimiceach Teiripeach Anatamaíoch) |
Dáta an fhógra |
||
|
14.2.2022 |
Apexxnar |
vacsaín chomhchuingigh niúmacocúil pholaisiúicríde (20-fhiúsach, ionsúite) |
|
EU/1/21/1612 |
Fuaidreán le haghaidh insteallta |
J07AL02 |
15.2.2022 |
||
|
14.2.2022 |
Ngenla |
somatrogon |
|
EU/1/21/1617 |
Tuaslagán le haghaidh insteallta |
Pending |
15.2.2022 |
||
|
14.2.2022 |
OKEDI |
rispeiriodón |
|
EU/1/21/1621 |
Púdar agus tuaslagóir d’fhuaidreán scaoilte fada le haghaidh insteallta |
N05AX08 |
15.2.2022 |
||
|
14.2.2022 |
Oxbryta |
voxelotor |
|
EU/1/21/1622 |
Piolla brataithe le scannán |
B06AX |
15.2.2022 |
||
|
14.2.2022 |
Saphnelo |
anifrolumab |
|
EU/1/21/1623 |
Tiúchán do thuaslagán le haghaidh insilte |
L04AA51 |
15.2.2022 |
||
|
16.2.2022 |
Kerendia |
finerenone |
|
EU/1/21/1616 |
Piolla brataithe le scannán |
C03DA05 |
17.2.2022 |
||
|
16.2.2022 |
Sapropterin Dipharma |
sapropterin |
|
EU/1/21/1620 |
Púdar le haghaidh tuaslagán béil Táibléid intuaslagtha |
A16AX07 |
17.2.2022 |
||
|
16.2.2022 |
Sitagliptin/Metformin hydrochloride Mylan |
sitagliptin/hidreaclóiríd mheatfoirmine |
|
EU/1/21/1619 |
Piolla brataithe le scannán |
A10BD07 |
21.2.2022 |
||
|
16.2.2022 |
Tepmetko |
tepotinib |
|
EU/1/21/1596 |
Piolla brataithe le scannán |
L01EX21 |
17.2.2022 |
||
|
21.2.2022 |
Ontilyv |
opicapon |
|
EU/1/21/1578 |
Capsúl, crua |
N04BX04 |
22.2.2022 |
— Údarú margaíochta a mhodhnú (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
2.2.2022 |
Vaxzevria |
|
EU/1/21/1529 |
2.2.2022 |
||
|
3.2.2022 |
Clopidogrel Viatris |
|
EU/1/09/568 |
7.2.2022 |
||
|
3.2.2022 |
DaTSCAN |
|
EU/1/00/135 |
9.2.2022 |
||
|
3.2.2022 |
Edarbi |
|
EU/1/11/734 |
8.2.2022 |
||
|
3.2.2022 |
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka |
|
EU/1/17/1263 |
9.2.2022 |
||
|
3.2.2022 |
Nyxoid |
|
EU/1/17/1238 |
7.2.2022 |
||
|
3.2.2022 |
Pregabalin Zentiva |
|
EU/1/15/1021 |
8.2.2022 |
||
|
3.2.2022 |
Vivanza |
|
EU/1/03/249 |
7.2.2022 |
||
|
3.2.2022 |
Voriconazole Accord |
|
EU/1/13/835 |
4.2.2022 |
||
|
3.2.2022 |
Xigduo |
|
EU/1/13/900 |
4.2.2022 |
||
|
4.2.2022 |
Cialis |
|
EU/1/02/237 |
8.2.2022 |
||
|
4.2.2022 |
Comirnaty |
|
EU/1/20/1528 |
4.2.2022 |
||
|
4.2.2022 |
Ebixa |
|
EU/1/02/219 |
8.2.2022 |
||
|
4.2.2022 |
Ebymect |
|
EU/1/15/1051 |
7.2.2022 |
||
|
4.2.2022 |
Entacapone Teva |
|
EU/1/10/665 |
8.2.2022 |
||
|
4.2.2022 |
HyQvia |
|
EU/1/13/840 |
7.2.2022 |
||
|
4.2.2022 |
Iressa |
|
EU/1/09/526 |
7.2.2022 |
||
|
4.2.2022 |
Neupro |
|
EU/1/05/331 |
9.2.2022 |
||
|
4.2.2022 |
Noxafil |
|
EU/1/05/320 |
8.2.2022 |
||
|
4.2.2022 |
Plegridy |
|
EU/1/14/934 |
9.2.2022 |
||
|
4.2.2022 |
Revolade |
|
EU/1/10/612 |
7.2.2022 |
||
|
4.2.2022 |
Roclanda |
|
EU/1/20/1502 |
10.2.2022 |
||
|
4.2.2022 |
Sivextro |
|
EU/1/15/991 |
8.2.2022 |
||
|
4.2.2022 |
Temozolomide Accord |
|
EU/1/10/615 |
9.2.2022 |
||
|
4.2.2022 |
Vantobra |
|
EU/1/18/1350 |
10.2.2022 |
||
|
4.2.2022 |
Yellox |
|
EU/1/11/692 |
14.2.2022 |
||
|
4.2.2022 |
Zoledronic acid Hospira |
|
EU/1/12/800 |
7.2.2022 |
||
|
10.2.2022 |
Ameluz |
|
EU/1/11/740 |
15.2.2022 |
||
|
10.2.2022 |
Axumin |
|
EU/1/17/1186 |
15.2.2022 |
||
|
10.2.2022 |
Cotellic |
|
EU/1/15/1048 |
14.2.2022 |
||
|
10.2.2022 |
Nityr |
|
EU/1/18/1290 |
15.2.2022 |
||
|
10.2.2022 |
Wakix |
|
EU/1/15/1068 |
3.3.2022 |
||
|
14.2.2022 |
Cubicin |
|
EU/1/05/328 |
18.2.2022 |
||
|
14.2.2022 |
Incruse Ellipta |
|
EU/1/14/922 |
4.3.2022 |
||
|
14.2.2022 |
Ivabradine Accord |
|
EU/1/17/1190 |
15.2.2022 |
||
|
14.2.2022 |
Spikevax |
|
EU/1/20/1507 |
16.2.2022 |
||
|
14.2.2022 |
Waylivra |
|
EU/1/19/1360 |
21.2.2022 |
||
|
14.2.2022 |
Xromi |
|
EU/1/19/1366 |
17.2.2022 |
||
|
16.2.2022 |
AMGLIDIA |
|
EU/1/18/1279 |
16.2.2022 |
||
|
16.2.2022 |
Besponsa |
|
EU/1/17/1200 |
17.2.2022 |
||
|
16.2.2022 |
CellCept |
|
EU/1/96/005 |
17.2.2022 |
||
|
16.2.2022 |
Deltyba |
|
EU/1/13/875 |
17.2.2022 |
||
|
16.2.2022 |
Eliquis |
|
EU/1/11/691 |
17.2.2022 |
||
|
16.2.2022 |
ellaOne |
|
EU/1/09/522 |
23.2.2022 |
||
|
16.2.2022 |
Envarsus |
|
EU/1/14/935 |
21.2.2022 |
||
|
16.2.2022 |
Febuxostat Mylan |
|
EU/1/17/1194 |
17.2.2022 |
||
|
16.2.2022 |
JEMPERLI |
|
EU/1/21/1538 |
17.2.2022 |
||
|
16.2.2022 |
Laventair Ellipta |
|
EU/1/14/899 |
4.3.2022 |
||
|
16.2.2022 |
Mayzent |
|
EU/1/19/1414 |
17.2.2022 |
||
|
16.2.2022 |
Modigraf |
|
EU/1/09/523 |
17.2.2022 |
||
|
16.2.2022 |
Myclausen |
|
EU/1/10/647 |
17.2.2022 |
||
|
16.2.2022 |
Pemazyre |
|
EU/1/21/1535 |
21.2.2022 |
||
|
16.2.2022 |
Pregabalin Sandoz |
|
EU/1/15/1011 |
21.2.2022 |
||
|
16.2.2022 |
Riximyo |
|
EU/1/17/1184 |
17.2.2022 |
||
|
16.2.2022 |
Temybric Ellipta |
|
EU/1/19/1378 |
4.3.2022 |
||
|
16.2.2022 |
Yuflyma |
|
EU/1/20/1513 |
2.3.2022 |
||
|
16.2.2022 |
Zykadia |
|
EU/1/15/999 |
17.2.2022 |
||
|
17.2.2022 |
Advagraf |
|
EU/1/07/387 |
21.2.2022 |
||
|
17.2.2022 |
Avonex |
|
EU/1/97/033 |
23.2.2022 |
||
|
17.2.2022 |
Mycophenolate mofetil Teva |
|
EU/1/07/439 |
18.2.2022 |
||
|
17.2.2022 |
Myfenax |
|
EU/1/07/438 |
21.2.2022 |
||
|
17.2.2022 |
Nexium Control |
|
EU/1/13/860 |
24.2.2022 |
||
|
18.2.2022 |
Tarceva |
|
EU/1/05/311 |
21.2.2022 |
||
|
18.2.2022 |
Zelboraf |
|
EU/1/12/751 |
21.2.2022 |
||
|
21.2.2022 |
Clopidogrel Taw Pharma |
|
EU/1/09/559 |
22.2.2022 |
||
|
21.2.2022 |
Jardiance |
|
EU/1/14/930 |
25.2.2022 |
||
|
21.2.2022 |
Ogivri |
|
EU/1/18/1341 |
23.2.2022 |
||
|
21.2.2022 |
Refixia |
|
EU/1/17/1193 |
24.2.2022 |
||
|
21.2.2022 |
Skilarence |
|
EU/1/17/1201 |
23.2.2022 |
||
|
23.2.2022 |
Tecentriq |
|
EU/1/17/1220 |
25.2.2022 |
||
|
24.2.2022 |
ADVATE |
|
EU/1/03/271 |
28.2.2022 |
||
|
24.2.2022 |
Bortezomib Hospira |
|
EU/1/16/1114 |
25.2.2022 |
||
|
24.2.2022 |
Briviact |
|
EU/1/15/1073 |
25.2.2022 |
||
|
24.2.2022 |
Irbesartan Teva |
|
EU/1/09/576 |
28.2.2022 |
||
|
24.2.2022 |
JEVTANA |
|
EU/1/11/676 |
28.2.2022 |
||
|
24.2.2022 |
Lacosamide UCB |
|
EU/1/19/1383 |
25.2.2022 |
||
|
24.2.2022 |
Rixathon |
|
EU/1/17/1185 |
25.2.2022 |
||
|
24.2.2022 |
Senshio |
|
EU/1/14/978 |
25.2.2022 |
||
|
28.2.2022 |
Comirnaty |
|
EU/1/20/1528 |
28.2.2022 |
||
|
28.2.2022 |
Imfinzi |
|
EU/1/18/1322 |
2.3.2022 |
||
|
28.2.2022 |
Nimenrix |
|
EU/1/12/767 |
1.3.2022 |
||
|
28.2.2022 |
Retsevmo |
|
EU/1/20/1527 |
2.3.2022 |
||
|
28.2.2022 |
Xagrid |
|
EU/1/04/295 |
1.3.2022 |
— Údarú margaíochta a tharraingt siar (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle)
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
3.2.2022 |
Vivanza |
|
EU/1/03/249 |
7.2.2022 |
— Údarú margaíochta a mhodhnú (Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
1.2.2022 |
Bravecto |
|
EU/2/13/158 |
3.2.2022 |
||
|
1.2.2022 |
Mirataz |
|
EU/2/19/247 |
2.2.2022 |
||
|
8.2.2022 |
Exzolt |
|
EU/2/17/212 |
9.2.2022 |
||
|
8.2.2022 |
Zulvac 8 Ovis |
|
EU/2/09/104 |
9.2.2022 |
||
|
10.2.2022 |
Draxxin |
|
EU/2/03/041 |
16.2.2022 |
||
|
10.2.2022 |
Nobilis IB 4-91 |
|
EU/2/98/006 |
14.2.2022 |
||
|
10.2.2022 |
Onsior |
|
EU/2/08/089 |
11.2.2022 |
||
|
28.2.2022 |
Innovax-ND-IBD |
|
EU/2/17/213 |
2.3.2022 |
||
|
28.2.2022 |
Innovax-ND-ILT |
|
EU/2/20/256 |
2.3.2022 |
Aon duine ar mian leis féachaint ar an tuarascáil mheasúnaithe phoiblí maidir leis na táirgí íocshláinte atá i gceist agus na cinntí a bhaineann léi, iarrtar orthu teagmháil a dhéanamh le:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |